Dynavax (NASDAQ: DVAX) reported Q3 EPS of $0.12, in-line with the analyst estimate of $0.12. Revenue for the quarter came in at $80.63 million versus the consensus estimate of $85.06 million.

Full Year 2024 FINANCIAL GUIDANCE

Dynavax is updating its full year 2024 financial guidance, based on the Company\'s current operating plan:

Narrowing HEPLISAV-B net product revenue range from approximately $265 to $280 million, to approximately $265 to $270 million
Reiterating HEPLISAV-B gross margin of approximately 80%
Reducing and narrowing research and development expense range from approximately $60 to $75 million, to approximately $55 to $65 million
Narrowing selling, general and administrative expense range from approximately $160 to $180 million, to approximately $170 to $180 million
Expect positive net income for full year 2024

For earnings history and earnings-related data on Dynavax (DVAX) click here.